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THE IMPACT OF FITBIT FLEX2 ON HEMOGLOBIN A1C  
IN PREDIABETICS  
JEREMY GADEN 
ABSTRACT 
 Type 2 Diabetes Mellitus (T2DM) is a growing healthcare problem in the United 
States that increases the risk for numerous health complications if left unidentified and 
untreated. Prediabetes, while not a clinical diagnosis, is a state of increased risk of 
developing T2DM based on elevated blood glucose laboratory markers such as 
hemoglobin A1C (HbA1C). There are numerous risk factors that predispose individuals to 
prediabetes and T2DM. Researchers have shown that targeting those risk factors that are 
modifiable, such as physical inactivity and obesity, with exercise and diet interventions 
can increase physical activity, decrease weight, decrease HbA1C, and decrease the 
incidence of T2DM in prediabetics.  
Tools such as pedometers that track physical activity in the form of step count can 
be used in interventions to improve upon these metrics. Researchers have also shown that 
pedometers can enhance interventions aimed at improving physical activity, weight, 
HbA1C, and incidence of T2DM.  
Recently, electronic tools that are wearable such as the Fitbit Flex2 have gained in 
popularity due to their additional interactive features with users. These electronic 
wearable devices employ behavior change techniques approved by the US Preventive 
Services Task Force to motivate individuals to be more physically active.  
		 vi 
Current research has shown that these electronic wearable devices enhance 
interventions aimed at improving physical activity, weight loss, and HbA1C in those with 
T2DM. Yet, there is a gap in current research that examines the effect that these devices 
have on HbA1C in prediabetics. The proposed study seeks to examine if the Fitbit Flex 2 
wrist device, in conjunction with a standard diet and exercise intervention, improves 
HbA1C measures in prediabetic individuals over a one-year period.  
Results from the proposed study could support the future use of these devices to 
help decrease HbA1C measures and the risk of development of T2DM and other T2DM-
health complications in prediabetics. Electronic wearable devices could alter the way in 
which clinicians monitor lifestyle interventions aimed at T2DM risk reduction and 
treatment. The use of electronic wearable devices may also serve as a more cost effective 
treatment alternative for those at risk of developing, as well as those diagnosed with, 
T2DM.  
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INTRODUCTION 
Background 
Diabetes Mellitus (DM) is a group of metabolic disorders characterized by 
hyperglycemia and classified into two broad groups based on the pathogenesis of the 
disease1. In Type 2 Diabetes Mellitus (T2DM), the disease usually occurs later in life and 
is defined as having a fasting plasma glucose (FPG) level ³ 126 mg/dL and a HbA1C ³  
6.5%2–4. The Centers for Disease Control and Prevention (CDC) estimated in 2012 that 
nearly 86 million Americans have prediabetes3. Prediabetes is defined as having a FPGL 
between 100-125 mg/dL and a HbA1C between 5.7-6.4%2–5.  
Risk factors for the development of T2DM include advanced age, ethnicity, 
obesity, and physical inactivity3,6. DM is a major risk factor for the development of 
cardiovascular disease (CVD)2,6. The staggering number of individuals with prediabetes, 
and the risk associated with DM and CVD, have led clinicians and researchers to apply 
interventions in the form of lifestyle changes to stop the progression of T2DM in those 
with prediabetes7. Finding successful lifestyle interventions to prevent the development 
of T2DM will improve the health and well-being of patients, decrease medical costs, and 
prevent co-morbid conditions such as obesity, hypertension, and dyslipidemia. 
One such lifestyle change that has been positively correlated with stopping the 
progression of T2DM in those with prediabetes is increasing physical activity7–11. 
Physical activity is defined by the National Institutes of Health (NIH) as “any body 
movement that works your muscles and requires more energy than resting”12. Walking 
and running are types of physical activity that can be quantified by step count. To aid in 
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the measurement of step count and quantification of physical activity, electronic wearable 
devices that are worn on the wrist, arm, torso, chest or leg can be utilized. The popularity 
of electronic wearable devices such as the Fitbit Flex2 with consumers has increased in 
recent years. The increase in popularity in electronic wearable devices and their ability to 
track health measures have translated into their use by consumers and researchers to 
monitor their health and medical interventions13.  
Statement of the Problem 
There has been an increase in prevalence in T2DM in both adults and those less 
than 20 years of age due primarily to the rise in obesity and physical inactivity among 
Americans2,14,15. The increase in the prevalence in T2DM and its association with CVD 
has led clinicians to identify those at-risk of developing T2DM through the use of routine 
screening of those with known risk factors for T2DM1.  Such risk factors for the 
development of T2DM include advanced age, family history of DM, obesity, ethnicity, 
and physical inactivity1,3,6. Routine screening tests include FPG and HbA1C1. 
The goal of identifying patients at-risk of developing T2DM is to employ specific 
interventions that have been shown to alter the natural history of the disease. For 
example, lifestyle changes in the form of physical activity and diet have been shown to 
lead to increased weight loss and a decrease in progression to diabetes in those that have 
prediabetes6,7.  
Wearable devices such as the Fitbit Flex2 can be used to track physical activity as 
a clinical intervention. A systematic review suggests that wearable devices in the form of 
simple pedometers that track daily step counts motivated individuals to increase the 
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amount of physical activity performed16. In addition, pedometer use was associated with 
decreases in blood pressure and BMI16. With the rise in popularity of wrist-watch style 
wearable devices, researchers have postulated that these devices also produce similar 
results by provoking behavior change through their ability to interact with a computer or 
mobile application allowing for self-monitoring, goal setting, feedback, and social 
interaction17–21.  
Current literature examines the role and impact of wearable electronic devices on 
increasing physical activity and motivating behavior change in a variety of medical states 
such as CVD, obesity, and post-surgical recovery11,22–24. There is a tremendous amount of 
literature that demonstrate lifestyle changes in the form of physical activity and weight 
loss are successful in preventing T2DM7–11,25–27. There are also systematic reviews and 
studies that examine the effect of accelerometers and pedometers on physical activity and 
glycemic control in persons with T2DM16,26–28. However, there remains a significant gap 
in current research that examines the relationship between wearable electronic devices 
and the prevention of T2DM in individuals with prediabetes. 
Hypothesis 
In prediabetic patients, a technology-enhanced intervention consisting of diet, 
exercise and a Fitbit Flex2 device will result in a lower HbA1C compared with a 
traditional intervention consisting of diet and exercise alone.  
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Objectives and specific aims 
This study proposes to examine the effects of the Fitbit Flex2 device on HbA1C levels 
in prediabetic individuals. Secondary aims of this study in prediabetic individuals 
include: 
• Quantifying the impact of the Fitbit Flex on Body Mass Index (BMI) 
• Quantifying the impact of the Fitbit Flex on physical activity level 
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REVIEW OF THE LITERATURE 
Overview 
Epidemiology of Diabetes Mellitus (DM) 
DM is a growing public health problem because of the increase in prevalence and 
the association with comorbidities such as CVD.  In 2012, the CDC estimated that 29 
million Americans had diabetes3,29. The American Heart Association (AHA) in 2016 
reported that nearly 186,000 people younger than 20 years of age and 21.1 million adults 
have diagnosed DM2. The AHA estimates that there are 8.1 million adults with 
undiagnosed DM2. Additionally, the CDC estimated in 2012 that 29 million Americans 
had diabetes, and nearly 86 million Americans have prediabetes3. Prediabetes is a state of 
increased risk of developing diabetes and CVD3,29.  
Among adults, the prevalence of DM has increased from 6.2% between 1988 to 
1994, to 9.9% between 2005 to 20102. Likewise, the incidence of DM for adults has 
nearly doubled since the 1970s, with an estimated 1.7 million new cases of DM 
diagnosed in 20122. While most individuals with T2DM are adults, there has been a 
30.5% increase in prevalence of T2DM in adolescents between 2001 and 20092. The 
increase in prevalence in T2DM in both adults (see Epidemiology of Diabetes Mellitus 
(DM), Overview, page 5) and those less than 20 years of age is due primarily to the rise 
in obesity and physical inactivity among Americans2,14,15. Among racial and ethnic 
groups, American Indians and Alaskan Natives are more than twice as likely to have DM 
than non-Hispanic whites (see Figure 1, APPENDIX A: FIGURES AND TABLES, page 
47)5. 
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Pathophysiology of DM 
Insulin serves as the key modulator of glucose homeostasis, although other neural 
and metabolic signals have a role in the regulation of glucose production and storage. 
Insulin is produced by the pancreatic beta cells and is secreted primarily in response to an 
increase in serum glucose levels. Once in the systemic circulation, insulin acts to bind at 
target sites in tissues where it sets off a series of phosphorylating and dephosphorylating 
reactions that lead ultimately to the uptake of glucose by cells and a reduction in serum 
glucose levels1. 
The pathophysiology of DM reveals four distinct groups of DM (see Table 1, 
(APPENDIX A: FIGURES AND TABLES, page 48). The most common and well known 
of the groups of DM are Type 1 DM (T1DM) and T2DM. T2DM occurs due to a 
decrease in the sensitivity of target cells to insulin which leads to an increase in insulin 
output by pancreatic beta cells1. Initially, this increase in insulin output can maintain 
near-normal glucose tolerance. Overtime though, the pancreatic beta cells begin to fail 
due to the prolonged, increased demand for insulin output, resulting in a decrease in 
insulin output. A subsequent period of impaired glucose tolerance (IGT) results1. IGT is 
defined as an elevation of serum glucose concentration after meals. The end result of 
decreased insulin and IGT is diabetes1. Additionally, there is an increase in hepatic 
glucose production as insulin serves to suppress gluconeogenesis in hepatocytes, and 
there is an increase in lipolysis in adipose tissue which results in an increase in lipid 
production and storage in hepatocytes1.  The increase in hepatic glucose production 
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results in increased FPG levels. Together, IGT and impaired FPG make up the period 
known as prediabetes. As target tissue insulin sensitivity continues to decrease, the period 
of IGT transitions to overt diabetes1.  
T2DM has a genetic component that predisposes one to disease development1. 
T2DM is also influenced by environmental factors such as obesity and physical 
inactivity. Obesity, especially central obesity, seems to play a particularly important role 
in the development of T2DM. An increase in byproducts of adipose tissue, in particular 
free fatty acids and adipokines, and a decrease in adiponectin, seem to further alter 
insulin sensitivity in target tissues1.  
Prediabetes Clinical Course 
 Prediabetes describes a state of hyperglycemia where blood glucose levels are not 
high enough to meet the diagnostic criteria for diabetes29. Prediabetes is defined as 
having a FPG level between 100-125 mg/dL and a HbA1C between 5.7-6.44,5,29. 
The ADA views prediabetes not as a clinical diagnosis but as a state in which 
individuals are at an increased risk for developing diabetes and CVD29.  This risk is 
evidenced by a systematic review by Zhang and colleagues of 16 cohort studies 
consisting of 44,203 individuals30. They found that “those with an [HbA1C] between 5.5 
to 6.5% had a substantially increased risk of diabetes (5-year incidence from 9 to 25%),” 
while those with a “[HbA1C] range of 6.0-6.5% had a 5-year risk of developing diabetes 
between 25 and 50% and a relative risk 20 times higher compared with [HbA1C] of 
5.0%”29,30. 
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The increased risk of developing T2DM from prediabetes has been shown to be 
preventable by interventions that target the modifiable risk factors of T2DM. Numerous 
studies show that interventions in the form of physical activity, weight loss, and 
medication such as metformin can prevent diabetes in individuals with IGT; additionally, 
these interventions improve glycemic control in individuals with T2DM 1,7–10,25,27. 
Screening and Diagnosing Prediabetes and T2DM  
Recommendations for screening for prediabetes and T2DM consider age and 
other known risk factors (see Table 2, APPENDIX A: FIGURES AND TABLES, page 
49). Recommendations for who to screen and screening tests to use are provided by the 
American Diabetes Association (ADA), as well as the U.S. Preventive Services Task 
Force (USPSTF) and the CDC (see Table 1 and Table 3, APPENDIX A: FIGURES AND 
TABLES, page 48 and page 50)31. Identification of risk factors for T2DM through 
gathering a thorough history and completion of a physical exam, and screening using 
laboratory tests are important because many individuals with DM do not exhibit classic 
symptoms of DM such as polyuria, polydipsia, polyphagia, and weight loss. In fact, there 
may be an extended period where individuals are asymptomatic but have hyperglycemia 
and meet criteria for T2DM1,4.  
The ADA has also developed and validated a non-invasive tool called the 
Diabetes Risk Calculator that clinicians can use to predict if an individual has 
undiagnosed diabetes or prediabetes and would benefit from confirmatory testing32. The 
tool consists of a flow chart with questions about known risk factors for diabetes, such as 
age, obesity (waist circumference), and race/ethnicity32.    
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HbA1C 
Hemoglobin is a protein in red blood cells that binds and transports oxygen1. 
Hemoglobin’s tetramer structure consists of different combinations of alpha and beta-like 
globin chains that code for hemoglobin variants, such as hemoglobin A1. HbA1C is a 
variant of hemoglobin A and is formed by the interaction of the hemoglobin with glucose 
over the course of the red blood cell lifespan, which is approximately three-months33. 
Additionally, the rate of HbA1C formation has been found to be directly proportional to 
red blood cell glucose levels33.  
The interaction between HbA1C and glucose, the rate of HbA1C formation, and the 
lifespan of red blood cells makes HbA1C an appropriate marker for blood glucose levels 
and glycemic control33. The HbA1C test is reported as a percentage and describes the 
average blood glucose levels over a three-month period34. An estimated glucose average 
is used to compare the HbA1C value to daily blood glucose levels34. The relationship 
between HbA1C and estimated average glucose is described as for every 1% change in 
HbA1C, there is a 30 mg/dL change in estimated average glucose33. The HbA1C test is 
performed by methods and standards approved by the National Glycohemoglobin 
Standardization Program (NGSP) aimed at establishing consistency and accuracy of 
measurements34. 
As the HbA1c measure is an average blood glucose measure over three-months, it 
does not reflect daily changes in blood glucose that may be present. Yet the measure is 
considered a weighted average, meaning more weight is given for the blood glucose 
levels closer to the measurement date then those farther away. As a result, the HbA1C 
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value is subject to influence by acute changes that may alter glycemic levels, such as 
illness and medications33. Additionally, although standards are in place to increase the 
accuracy of the HbA1C value, it should be noted that the actual value may be 0.5% lower 
or higher than the measured value. This degree of accepted difference between the 
measured and actual value is attributed to variability in the laboratory in which the 
measurement is performed34. 
Additionally, the accuracy of the HbA1C value can be impacted by factors such as 
age, race and ethnicity, and conditions such as anemia, heavy bleeding, and 
hemoglobinopathies such as sickle cell33,34. The presence of any of these factors or 
conditions could produce a false-positive result, and warrants testing by a method 
approved for these variants by the NGSP34. 
The HbA1C test is used as both a diagnostic and monitoring test of those with IGT 
and DM34. After a diagnosis of DM, the ADA recommends a HbA1C test be performed 
two-times per year if blood glucose levels are well controlled, and up-to four-times per 
year until goal glucose levels are met29. 
 T2DM Complications 
Medical complications associated with T2DM include eye problems such as 
retinopathy, nephropathy, neuropathy, and frequent infections that may lead to 
amputations3,4. In addition, hypertension is known to further exacerbate many of the 
medical complications caused by T2DM4. As a result, routine monitoring and medical 
care for these medical complications through eye exams, foot exams, blood pressure 
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measurement, lipid and serum creatinine measurements, and immunizations are 
recommended1.  
Abnormal glucose control and thus T2DM is a major risk factor for CVD2,6,35. It 
is important to note that many of the risk factors for the development of CVD, such as 
obesity, physical inactivity, and unhealthy diet, are also shared by prediabetes and 
T2DM35.  
Electronic wearable device history and technology 
Today, the term electronic wearable devices refers to the many different devices 
that are worn on various parts of the body that incorporate technology able to objectively 
measure a health metric and then communicate that data to the user8. Their current use as 
fitness trackers dates their origins to simple mechanical pedometers that record daily step 
counts36. Mechanical pedometers rely on a swinging pendulum and a series of gears that 
advance a number counter with every step taken36. Reports from Japan in the 1960’s 
show pedometers were used to track physical activity in walking clubs37. It is said that at 
these walking clubs Dr. Yoshiro Hatano coined the “10,000 step” rule that established a 
goal for physical activity based on walking, using estimates of the metabolic equivalent 
of task (MET) for walking37. A MET is a unit commonly used to describe the amount of 
energy expended during physical activity38. Dr. Hatano reasoned that 10,000 steps 
equated to approximately 300 MET-minutes37. For reference, current guidelines have set 
MET-minute targets to 500-1000 per week of physical activity to translate into a health 
benefit38.  
	12 
Two downsides of pedometers are that they only reflect one type of bodily 
movement (i.e. walking/running) and they do not reflect movement intensity. As physical 
activity is defined as any bodily movement that requires the use of energy, the use of an 
accelerometer was suggested in the 1970s to better estimate physical activity in terms of 
amount and intensity12,39. Accelerometers consist of a group of “sensors which measure 
the acceleration of objects in motion along reference axes”40. Yang et al support the use 
of accelerometry to measure physical activity because “acceleration is proportional to 
external force and hence can reflect intensity and frequency of movement”40. Work by 
Morris in 1972 demonstrated that an accelerometer attached to the antero-medial tibia 
could accurately measure the movement of the lower leg39. His initial accelerometer was 
five accelerometers mounted on a platform and held in place on the body surface by a 
foam like cast. Movement signals were recorded on a portable tape recorder or through a 
cable connected to a fixed recorder. Computers were then used to analyze the signals 
from the accelerometer via mathematical formulas that considered velocity, acceleration, 
time, and position of body part39.  
The first wearable device that relied on batteries, the Sports Tester PE2000, was 
released in 1982 by a Finnish company called Solar41,42. The Sport Tester PE 2000 
consisted of a chest strap that recorded an EKG and a wrist strap that received heart rate 
data from the chest strap via radio signals43. The first blue tooth phone in 2000, followed 
by Garmin releasing a GPS device worn on the wrist in 2003, set the stage for the 
company Fitbit to develop a device used for physical activity44. Apple’s version of a 
smartphone, the iPhone, was released in 2007 and combined internet accessibility, 
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numerous software applications, and a built-in accelerometer and gyroscope 44,45. The 
gyroscope served to measure the rate of rotation across the 3 accelerometer axes46. Fitbit 
released the FitBit Classic in 2008 which was worn at the wrist47. Fitbit used a 3-axis 
accelerometer to track body movement. Analysis of the movement was completed inside 
the wrist worn device by an algorithm that translated movement into step counts, unlike 
Morris’ accelerometer model that used a separate computer for movement analysis. Other 
measures produced from the 3-axis accelerometer include distance traveled, calories 
burned, and sleep quality48.  
The smartwatch is the latest iteration of an electronic wearable device produced 
by companies like Apple, Samsung, Sony, and Google49. It incorporates features of other 
electronic wearable devices, like sensors and the ability to measure physical activity and 
movement, with additional features like the ability to make a phone call, in a classic 
watch-like display49. One such smartwatch, the Apple Watch, incorporates an 
accelerometer and gyroscope, as well as a barometer, that measures pressure. The 
addition of a pressure reading aids in calculating elevation changes such as when walking 
up a set of stairs, providing a more accurate measurement of movement46.  
Central to smartphones and electronic wearable devices are software programs 
called applications, or “apps,” that are acquired through the device’s operating system 
store. Apps provide a service to the device user, such as promoting health and wellness, 
and are able to interface with computers, mobile devices, and wearable devices50–52. Such 
health and wellness apps, coined mobile health or mHealth apps, “are mobile device 
applications intended to improve health outcomes, deliver health care services, or enable 
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health research”51. mHealth apps have been found to employ a variety of behavior change 
techniques (BCT) that are associated with changes in physical activity and are 
recommended by the USPSTF to aid in increasing physical activity53–57. The most 
prevalent BCTs used by mHealth apps and wearable devices include self-monitoring, 
activity feedback, activity instruction, goal-setting and review, social support, and social 
comparison. The BCTs listed above employ visualizations in the form of charts, graphs, 
and lists that compare one’s progress to other users in the mHealth apps to motivate 
individuals to improve health outcomes (see Figure 2 and Figure 3, APPENDIX A: 
FIGURES AND TABLES, page 51 and page 52) 52,58.  
mHealth apps have also been found to employ strategies that aim to increase 
usage via “gamification of activity with competitions and challenges, publication of 
visible feedback on performance utilizing social influence principles, [and] 
reinforcements in the form of virtual rewards for achievements”59. With their ability to 
collect data and their potential to motivate behavior via BCTs, wearable devices have the 
potential to subjectively measure the effectiveness and progress of physical activity 
interventions59,60. 
The Fitbit Flex, and its newest iteration the Fitbit Flex2, are examples of wrist 
worn devices that incorporate popular BCTs recommended by the USPSTF to aid in 
increasing physical activity52,56,58,61. These BCTs include the Fitbit App that enables 
continuous self-monitoring of physical activity through a mobile device or desktop 
dashboard, activity feedback in the form of notifications such as reminders to move and 
goal celebrations, and the ability to interact socially with other Fitbit users52,53,55–58,61,62. 
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Accuracy and validity of electronic wearable devices 
Electronic wearable devices can collect numerous measures that define physical 
activity such as step count, energy expenditure, and heart rate65. As increasing one’s step 
count is a measure of physical activity that is positively correlated with improvement in 
weight loss, the ability of electronic wearable devices to accurately and reliably capture 
step count is vital to assessing the health and effectiveness of physical activity 
interventions63. 
Factors impacting the degree of accuracy of measured step count can be the type 
of device and location of device placement on the body. Numerous studies have 
examined the effect that different devices, as well as device location such as on the hip 
and wrist, have on accuracy of measured step count 63–66. Review of recent literature 
shows that hip based devices are overall more accurate than wrist based devices, 
especially at slower walking speeds. Yet wrist based devices have demonstrated to be 
highly accurate at measuring step count63,65,66. For example, Dominick et al compared 
step counts in the Fitbit Flex worn at the wrist to the ActiGraph GT3X worn at the hip. 
Their results showed that there was no significant difference between the daily step count 
between the Fitbit Flex and the ActiGraph GT3X (r = 0.91, p = 0.10)66. 
These results support and open the door for the use of wrist based electronic 
devices in future clinical studies that assess physical activity. Yet researchers have also 
questioned the generalizability of these results to individuals with chronic disease 
whether these devices are accurate in populations with disease67. Further analysis and 
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discussion of the accuracy, generalizability, and application of electronic wearable 
devices can be found in APPENDIX B: DEVICE ACCURACY, page 55. 
Electronic wearable devices in consumer and research markets 
The use of electronic wearable devices has been adopted by both the consumer 
and research markets in recent years52. Their popularity in health and wellness is signified 
not only by the number of estimated users and clinical trials that use a device, but also by 
the saturation of the market with device models and mHealth apps. According to Wright 
et al, there were 414 electronic wearable device models able to monitor physical activity 
available for purchase by consumers in November 201613. Similarly, Powell in 2013 
reports that there were nearly 40,000 mHealth apps available for purchase by 
consumers51.  
Consumer estimates of electronic wearable device usage vary from 1% to 10% of 
the U.S. population, with usage expected to increase significantly in the 
future13,19,20,59,68,69. A 2016 Pricewaterhouse Coopers poll of 1,000 individuals 
representative of census race and ethnicity data found that nearly half of respondents 
owned an electronic wearable device20. Those that owned a device were most likely to 
either own a fitness band such as a Fitbit (47%) or a smartwatch like the Apple Watch 
(12%). They also found that health was the number one reason for purchase20. A recent 
Pew Internet Research Poll found that 69% of U.S. adults track at least one health 
indicator, such as blood pressure or weight70. And nearly 1 in 5 of those people that track 
use some form of technology to track their data70. Their findings highlight that those with 
chronic diseases are more likely to track health indicators such as symptoms, with an 
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increased likelihood of tracking the more chronic diseases one has70. However, their poll 
found “that people living with one or more chronic conditions are no more likely than 
other U.S. adults to track their weight, diet, or exercise routine70. These findings, which 
report an increased use of health indicator tracking and technology use, also correlate 
with observations from others that the most likely people to purchase and use electronic 
wearable devices that track physical activity are those that are young, relatively healthy, 
and need them the least19,59,70. 
Additionally, the Pew report found that tracking health indicators using any form 
of tracking (paper, technology, etc) has a positive impact on one’s health approach, 
maintenance and decision making concerning health matters70. This finding, along with 
the gap seen in electronic wearable device usage in people with chronic diseases, as noted 
above, highlights the potential for the use of electronic wearable devices as a modality for 
tracking health indicators in chronic disease and medical interventions.  
Researchers have noticed this potential as evidenced by the ubiquitous use of 
electronic wearable devices in current clinical trials to track the effect of physical activity 
as a medical intervention13,71. A search of clinicaltrials.gov conducted by Wright et al in 
November 2016 found that physical activity devices produced by Fitbit were being used 
in 127 clinical trials13. The other top physical activity devices/companies represented in 
their search include Jawbone, Apple Watch, Garmin, and Polar13. The authors note that 
there has been a rapid increase in the number of publications, clinical trials, and research 
grants awarded since 2010 that use Fitbit devices13. The majority of these trials use the 
Fitbit in interventional studies to evaluate if these devices act as a “motivational 
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intervention to promote physical activity and weight management with the goal of 
improving health outcomes in populations ” that are obese and have diabetes13. 
Additionally, Wright et al have found that the primary outcome that is tracked using 
these devices is physical activity13.  
Existing research 
Prediabetes is a state of IGT that confers increased risk for development of T2DM 
and long-term systemic sequelae3,4,29. Interventions that target risk factors deemed 
modifiable are vital at decreasing the incidence and development of T2DM in individuals 
with prediabetes. Various studies have examined the impact of lifestyle interventions on 
HbA1C, and modifiable risk factors of physical activity, diet, and weight loss at 
preventing T2DM7–11,25. Studies have also examined the changes in physical activity, 
weight loss, HbA1C, and incidence in T2DM due to the use of pedometers and electronic 
wearable devices in individuals with prediabetes and T2DM16–18,21,26–28,72–74.  
Preventing T2DM with lifestyle changes 
There are numerous risk factors for the progression of T2DM in at risk 
individuals (see Prediabetes Clinical Course, Overview, page 7; and Table 2, 
APPENDIX A: FIGURES AND TABLES, page 49). Many of these risk factors, such as 
physical inactivity and obesity, are modifiable, leading researchers in the Da Quing IGT 
and Diabetes Study to investigate the effect of diet and exercise on preventing T2DM 
with IGT7. After a six-year period, the cumulative incidence of T2DM was 67.6% in the 
control group (95% confidence interval (CI), 59.8-75.2), which is significantly (p <0.05) 
higher when compared 43.8% in diet intervention group (95% CI, 35.5 to 52.3), 41.1% in 
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the exercise group (95% CI, 33.4 to 49.4), and 46% in the diet and exercise group (95% 
CI, 37.3 to 54.7)7. The results of this study highlight that interventions consisting of diet, 
exercise, and diet with exercise are effective at reducing the incidence of T2DM7.  
Investigators in the Diabetes Prevention Program (DPP) examined the effects of 
lifestyle interventions on non-diabetic individuals with IGT and therefore at high risk of 
developing T2DM8. Participants were randomized into one of three intervention arms: 
standard lifestyle recommendations plus metformin twice daily, standard lifestyle 
recommendations plus placebo twice daily, or an intensive lifestyle modification 
program8. The mean HbA1C was 5.91% +/- 0.5 for all three study arms. Their findings 
showed that there was a significant difference in the incidence of diabetes among the 
three groups, with the lowest incidence in the intensive lifestyle group, followed by the 
metformin group, and lastly the placebo group8. They documented that the intensive 
group was more effective at losing weight, maintaining weight loss, and had a lower 
HbA1C than the metformin and standard group. Pertaining to HbA1C, the difference 
between the groups was statistically significant from 0.5 to three years (p < 0.001)8. The 
authors concluded that when compared to placebo, the intensive intervention reduced the 
risk of newly diagnosed T2DM by 58% (95% CI, 48-66)8. Similarly, when compared to 
metformin, the intensive lifestyle intervention reduced the incidence by 39% (95% CI, 24 
to 51)8. This markedly significant reduction in the risk for progression of T2DM is the 
reason why investigators discontinued the study one year early. Importantly, they 
reported that the reduction in incidence is similar across gender and in all racial and 
ethnic groups8. 
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In 2002, the Diabetes Prevention Program Outcomes Study (DPPOS) continued 
the original DPP study to investigate the long-term effects of lifestyle interventions on 
diabetes incidence10. The DPPOS consisted of the same three intervention arms as the 
original DPP study, but with changes that included participants in the metformin and 
placebo groups being unmasked to their treatment assignment, and cessation of placebo. 
All participants were offered a group version of the original lifestyle curriculum which 
served as a ‘bridge’ between the DPP study and DPPOS. Additionally, the lifestyle 
intervention arm was offered four group sessions each year10. 
The DPPOS investigators concluded after a 10-year period that incidence rates in 
diabetes “did not differ significantly between groups… [and rates] were stable in the 
lifestyle group, but fell in the placebo and metformin groups”10. An analysis of the DPP, 
bridge, and DPPOS periods showed that the incidence of diabetes was reduced by 34% in 
the lifestyle group (95% CI, 24 to 42) and 18% in the metformin group (95% CI, 7 to 28) 
when compared to the placebo group10. HbA1C was found to be lower in the lifestyle and 
metformin groups than compared with the placebo group. Additionally, investigators 
were able to estimate the median delay to onset of diabetes to be four years by lifestyle 
and two years by metformin when compared with placebo10. Regarding weight loss, the 
lifestyle group that lost the most weight initially still weighed less than at onset of DPP 
period but had regained some of that weight back10. The metformin group was better able 
to maintain their weight loss throughout the DPP, bridge, and DPPOS periods for all 
groups10. One of the more remarkable findings from this study is that 13% of the lifestyle 
group were normoglycemic based on ADA criteria at the most recent yearly exam prior 
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to publication, compared to 11% of the metformin group and 10% of the placebo group10. 
Together, these results demonstrate that lifestyle changes in the form of physical activity 
and diet are as effective, if not more effective, than medication at preventing the 
progression of T2DM in individuals with prediabetes. 
Hamman and colleagues examined the contribution of diet and physical activity in 
the lifestyle group of the DPP study9. Using a Cox proportional hazards model, 
investigators found that weight loss had the strongest association with lower diabetes 
incidence (hazard ratio 0.81 per 10-kg weight loss, p < 0.0001, hazard ratio 0.49 per 5-kg 
weight loss, p < 0.0001)9. Their model does not show that physical activity changes were 
related to diabetes incidence, but that increased physical activity was a predictor of 
weight loss9. Furthermore, their analysis estimates that for every 1kg of weight loss there 
is a 16% reduction in risk of the development of T2DM in individuals with IGT9.  
One limitation that is identified in the Hamman et al analysis and subsequently 
the DPP study is that physical activity and diet were self-reported through a weekly 
activity recall survey and an annual questionnaire8,9. Self-reporting could result in recall 
bias that could ultimately skew the contribution of physical activity and diet on diabetes 
incidence. Yet, as Hamman and colleagues point out, diet and activity were both 
“significantly associated with weight loss”9. 
The DPP findings are consistent with a randomized, unmasked Finnish study 
published in 2001 that examined the effect of lifestyle changes on T2DM prevention in 
individuals with IGT25. The intervention group had a goal of 5% weight reduction or 
more, goals pertaining to diet and exercise, and received personalized education 
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pertaining to diet and exercise to aid in achieving those goals. Their results showed that 
weight loss was significantly greater for the intervention group than the control group at 
the end of year one and two (p < 0.01), with 43% of participants in the intervention group 
achieving greater than 5% weight reduction as opposed to 13% in the control group by 
year one25. Although this study did not measure HbA1C, there was a statistically 
significant difference in FPG (p < 0.01) and 2-h PG (p = 0.003) between the two 
groups25. They also found that the incidence of newly diagnosed T2DM after four years 
was 11% (95% CI, 6 to15) for the weight loss intervention group and 23% (95% CI, 17 to 
29) for the control group25. Consistent with the DPP’s initial findings, there was a 58% 
reduction in the development of T2DM in overweight individuals (p < 0.001)25. 
There are weaknesses to the Finnish study that make their results less 
generalizable. First, the study size of the Finnish study was 522 individuals as compared 
to 3234 individuals in the DPP study8,25. The Finnish study was underpowered and at 
high risk for a type 2 error. Furthermore, race and ethnicity of participants in the Finnish 
study was not reported25. While many of the risk factors for developing T2DM are 
reported and represented, such as advanced age and elevated BMI, it is difficult to 
generalize the Finnish findings to individuals in the U.S. because race and ethnicity has 
been shown to have a high association with the development of T2DM5. 
The Look AHEAD Trial is another study that examined the effect of intensive 
lifestyle interventions on  HbA1C, as well as CVD events, in persons with T2DM11,75. The 
intervention group participated in an intensive lifestyle intervention consisting of in-
person group and individual counseling sessions, along with exercise, diet, and weight 
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loss goals; the control group participated in a standard group counseling program that 
focused on diet, exercise, and social support and met three times a year.  Across four 
years, investigators found that there was a greater improvement in HbA1C levels in the 
intervention group than the control group that was statistically significant (intervention 
group: −0.36%, 95% CI, -0.40 to -0.33; control group: −0.09%, 95% CI, -0.13 to -0.66; p 
< 0.001)11. The lower HbA1C in the intervention group compared to the control group was 
also seen across 10 years, which was reported as a main effect of -0.22 (95% CI, -0.28 to 
-0.16; p < 0.001)75. The authors concluded after 10 years that there was no significant 
reduction in CVD events between the intervention group and the control group (hazard 
ratio 0.95, 95% CI, 0.83 to 1.09; p = 0.51). Yet, there were  significantly greater 
improvements in other CVD and T2DM risk factors, such as weight and waist 
circumference75.  
Pedometers: improving physical activity and reducing incidence of T2DM 
Bravata et al published a systematic review in 2007 that examined the relationship 
between pedometers and physical activity and health outcomes16. They concluded that 
“pedometer use is associated with significant increases in physical activity – a magnitude 
of about 2000 steps or about 1 mile of walking per day”16. An association was also found 
with two BCTs, goal setting and diary use to track progress16. The investigators reported 
that participants in studies that had a goal and used a diary significantly increased their 
step count over those that did not use these strategies16. Importantly, their findings 
suggest that pedometer users had reductions in both BMI and systolic blood pressure16. 
As noted earlier, an elevated BMI is a risk factor for development of T2DM1,4. In terms 
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of the BMI finding though, the authors report that they are unable to attribute weight loss 
solely due to an increase in number of steps as they were unable to determine the 
contribution of dietary counseling in their analysis16. 
One study included in the above systematic review from Tudor-Locke et al 
examined the effect of a physical activity intervention on overweight/obese individuals 
with T2DM26. The physical activity intervention was the First Step Program (FSP), a 
program that emphasized BCTs such as social support, goal setting, self-monitoring, 
feedback, and encouragement to increase walking over four-weekly group meetings at the 
beginning of the trial. Self-monitoring, goal setting, and feedback were facilitated by the 
use of pedometers that tracked step count and had been shown to record within 1% of 
steps taken under control settings in obese individuals76. Due to the prior diagnosis of 
T2DM, all of the participants were previously started on a treatment regimen of diet 
alone or oral hypoglycemics26.  
At 16-weeks, Tudor-Locke et al found that those in the intervention group with 
the pedometer had significantly increased their step count by approximately 3,000 
steps/day from baseline (p < 0.01)26. Other measures such as weight and BMI were 
unchanged between both groups, although investigators found an inverse relationship 
between step count, change in glycemic markers, and change in triglyceride 
concentrations in the intervention group that was statistically significant (r = -0.43, p = 
0.04). These inverse relationships were especially evident in those that were taking 
hypoglycemic medication (r = -0.76, p = 0.01)26. Their findings at 24 weeks were less 
conclusive about the impact of the FSP intervention; the intervention group still had 
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completed more steps/day than the control group, but the change was no longer 
statistically significant, and the inverse relationship between step count and blood glucose 
markers was no longer present26. 
The results from the Tudor-Locke et al study show that a pedometer can be a tool 
used to increase physical activity and improve glycemic control in individuals with 
T2DM26. Though results did not show pedometers had an effect on weight and BMI26. 
Also, the physical activity reporting protocol used that required the return of the 
pedometer to investigators and step count correction highlights an opportunity for more 
advanced technology that electronically reports data to be used to track steps in future 
trials26. 
Diedrich et al examined the change in HbA1C with the use of pedometers in 
individuals with T2DM. Participants were recruited from current participation in a 
diabetes self-management program that emphasized changes in physical activity, diet, 
and glycemic monitoring among others. After three-months, significant decreases in 
HbA1C were seen in both the pedometer group (t = 3.81, p = 0.02) and the control group 
(t = 3.28, p = 0.05)27. Yet, comparison of the pedometer and control group to change in 
HbA1C showed no significant difference between the two groups (t = 1.15, p= 0.107)27. 
Additional results showed a significant decrease in weight for both groups, as well as 
increase in physical activity (steps) for the pedometer group. Diedrich and colleagues 
suggest that while pedometers may enhance interventions that focus on exercise, diet, and 
weight loss to reduce HbA1C, interventional programs alone may be sufficient at 
improving T2DM modifiable risk factor behaviors27. Yet, two major features that 
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decrease the strength of their results are the small sample size (n = 33), and short length 
of the study (three months).  
Electronic wearable devices: improving weight, physical activity, and T2DM incidence  
Several studies have examined the effect of electronic wearable devices have on 
health measures like weight. Shuger et al used the SenseWear Armband (SWA) that is 
worn on the upper arm with a feedback display and that links up with an online website 
used for self-monitoring and feedback18. The study comprised of three arms over a nine-
month period in overweight and obese individuals: weight loss program; use of the SWA 
alone; and use of the SWA in combination with a group weight loss program18.  The 
authors found that “there was significant weight loss in all three intervention groups 
(group weight loss 1.86 kg, p = 0.05; SWA-alone, 3.55 kg, p = 0.0002; group weight loss 
and SWA, 6.59 kg, p < 0.0001) but not in the [control] group (0.89 kg, p = 0.39)” at the 
end of the nine-month study18. The investigators also found that the SWA-group weight 
loss program group was the only group to achieve significant weight loss after nine 
months when compared to the control group (p =0.04)18. The authors conclude based on 
these findings that the use of electronic wearable devices that allow for continuous, real-
time self-monitoring can enhance lifestyle interventions in overweight and obese 
individuals pursuing weight loss18. 
Polzien et al demonstrated that the addition of an armband device to a face-to-
face intervention resulted in greater weight loss than the standard intervention after three 
months21. There were three arms in this study with each group receiving seven in-person 
diet and exercise education sessions; the two intervention groups were given a SWA to 
	27 
wear on their upper arm, with one group wearing the armband continuously and using the 
internet website daily to log and upload results, while the other group wore the armband 
intermittently and used paper diaries to log their results when not using the device. 
Investigators found that there was a statistically significant weight loss for all groups (4.1 
+/- 2.8kg control group, 3.4 +/- 3.4kg intermittent armband use, 6.2 +/- 4.0 kg continuous 
armband use, p < 0.05)21. The data does show that the continuous SWA group lost more 
weight than both the intermittently used SWA group and the control group, yet these 
differences were not statistically significant (p = 0.08)21. Yet the authors point out that 
while not statistically significant, a 2kg weight loss difference may be clinically 
significant. The results reveal that an electronic wearable device can aid in weight loss in 
obese individuals and that wear time may be an important factor in outcomes21.  
There are numerous features of the Polzien and Shuger trials related to electronic 
wearable devices that are worth noting that strengthen these studies. First, the ability of 
study participants to interact with a display on their arm and receive real time feedback 
on progress serves as a BCT that has been shown to influence behavior52,58–60. Second, 
the use of a website to upload and enter results is both convenient and efficient for study 
participants and investigators. Lastly, while Polzien and colleagues reported that there 
was no significant difference between groups with the completion of the intervention, the 
use of technology may have the ability to enhance compliance and retention in study 
completion21. 
Jakicic and colleagues examined the effect of an electronic wearable device on 
weight loss over a 24-month period 17. The device used in their study was the FIT Core 
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produced by Body Media that is worn on the upper arm and has an online website that 
tracks physical activity measures. Unlike other studies, this trial did not randomize 
participants until after six months of diet and physical activity education and counseling 
sessions. The two arms of the trial consisted of the control group that self-reported 
physical activity and diet on a website, and the intervention group that used the Fit Core 
device and corresponding website to monitor results17. Additionally, monthly group-
based sessions and weekly phone calls and text messages were scheduled during months 
7-2417. Investigators found that while the mean estimated weight was lower across both 
groups over 24-months (control group: 5.9 kg, 95% CI, 5.0 to 6.8; intervention group: 3.5 
kg, 95% CI, 2.6 to 4.5), the mean estimated weight loss was lower for the control group 
and the weight loss difference between the two groups was statistically significant (2.4 kg 
difference, 95% CI, 1.0 to 3.7; p = 0.002)17These results imply that the device “was less 
effective” at producing weight loss than the standard intervention, suggesting that 
technology may not be as an effective motivator for behavior change when compared to a 
standard weight loss intervention17.  
One criticism of the Jakicic and colleagues study is that the delay in using the 
device until after six-months of counseling and education may have hindered the 
adoption of the device and therefore altered the effect on weight loss17. Another 
drawback from this device is that data may not be generalizable to other age groups as the 
median age of study participant was 30.9 years. However, results are generalizable to 
groups with elevated BMI as inclusion criteria required a BMI between 25 and 40 kg/m2, 
which resulted in a median BMI of 31.2 kg/m2. Lastly, the authors suggested that the 
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placement of the device on the upper arm may not be as accurate as the newer wrist-
based devices at tracking physical activity measures17. Inaccurate data could alter 
participant’s interpretation of physical activity and self-monitoring, which could then 
impact future behavior and ultimately weight loss.  
Less is known regarding the effect of current electronic wearable devices, 
especially those worn on the wrist, and the groups with T2DM and prediabetes. Recent 
work by Miyauchi et al examined the effect of an activity monitor that recorded steps, 
walking time, and interacted with the user, compared to a pedometer that recorded steps 
and activity time, on change in HbA1C in individuals with T2DM72 . The intervention 
consisted of an exercise program with activity goals of 8,000 steps and 20 minutes or 
longer of moderate intensity walking per day over a six-month period. Investigators 
found that both groups had a significant change in HbA1C from baseline at two months (-
0.24 +/- 0.39 activity monitor group; -0.08 +/- 0.42 pedometer group; p < 0.001). They 
also found that the difference between the two groups at two months was significant (p < 
0.05)72. While a statistically significant decrease in HbA1C was seen in both groups from 
baseline to six-months (-0.37 +/- 057 activity monitor group; -0.31 +/- 0.48 pedometer 
group; p < 0.01), the differences between groups was not significant72. An additional 
analysis that excluded participants that had met less than 80% activity goals and had 
changes in medications prior and during the study (n = 28) revealed a significant change 
in HbA1C at two months from baseline for both groups (-0.24 +/- 0.16 activity monitor 
group; -0.01 +/- 0.23 pedometer group; p < 0.001); the difference between groups was 
also significant (p < 0.05)72. At six months, a change in HbA1C was also seen in both 
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groups, but only the change in HbA1C in the activity monitor group was significant (-0.28 
+/- 0.50; p < 0.001). Additionally, the differences between groups was not significant72. 
One criticism of the Miyauchi et al study deals with the device placement around 
the neck and the accuracy of such a device at tracking physical activity measures. 
Additionally, this study is short, and while significant changes in HbA1C were seen in the 
short term, these differences dissipated at six-months.  
A systematic review by Baskersville et al examined the relationship between 
accelerometers and pedometers on physical activity and glycemic control in individuals 
with T2DM28. They found that three of the 12 studies included in their analysis were 
designated as using accelerometers. They defined accelerometers as devices “that can log 
time and intensity of activity”28. Yet they chose to exclude studies in which 
accelerometer devices were used in conjunction with a smartphone app, as these apps 
may influence physical activity behavior by BCTs not related to one monitoring their 
physical activity28. This feature of their study is a major drawback because apps are a 
major component of current electronic wearable devices that employ numerous BCTs 
shown to influence behavior52–60. Furthermore, one of the studies in the systematic review 
labeled as ‘accelerometer’ used an accelerometer worn at the waist to track physical 
activity77. While results show that physical activity in their intervention group with the 
accelerometer increased more over the three month trial than the control group, the 
generalizability of these results may be limited because of the use of the waist-based 
device77.  
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Recently, a trial proposal examining the effect of a physical activity intervention 
and the use of an wrist-based electronic wearable device in individuals with T2DM on 
HbA1C was published73. The device to be used in this trial will be a Fitbit Blaze wrist 
device that can track physical activity and diet through an accompanying app and 
website. The authors state that “to [their] knowledge, this will be the first study to 
promote physical activity in diabetic patients that utilizes a consumer wearable devie”73. 
The authors hypothesize that a consumer device like the Fitbit Blaze has the potential to 
increase the likelihood that a physical activity intervention is sustained, and could serve 
as an adequate substitution to more expensive interventions such as gym memberships73. 
While findings of this trial, when published, may further support the use of electronic 
wearable devices in populations that undertake physical activity interventions, the study 
population that will be used are already diagnosed with T2DM. 
An additional study that examines the use of a Fitbit device in conjunction with a 
physical activity intervention in obese youth has recently completed the data collection 
phase of their trial74. It is unclear what the baseline status of serum glucose markers were 
for individuals in this study, as the major inclusion criteria for participation are a BMI ³ 
85th percentile and an age between 13-18 years old. They additionally will not be 
reporting on the effect of the intervention on serum glucose markers, as the primary 
outcome measures are a BMI, physical activity, and blood pressure74. While obesity is a 
known risk factor for development of T2DM, these results will be limited in their 
generalizability to other age groups given this study’s age requirement74.  
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The existing literature demonstrates that lifestyle changes in the form of diet and 
exercise decrease the incidence of T2DM. In addition, lifestyle changes with the aid of 
pedometers and electronic wearable devices are effective at increasing physical activity, 
decreasing weight, decreasing the incidence of T2DM, and decreasing HbA1C in 
individuals with T2DM. Yet, no studies to date have examined the use of electronic 
wearable devices and their impact on HbA1C in prediabetic individuals. The proposed 
study will examine the effect of electronic wearable devices on HbA1C in this population.  
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METHODS 
Study design 
This study will be a prospective, randomized clinical trial conducted in Boston, 
MA. The identity of the research group of each participant will be known to investigators. 
This study will be fully approved by the Boston Medical Center (BMC) Institutional 
Review Board (IRB) (see Institutional Review Board, page 40). 
Study population and sampling 
Investigators will recruit participants that receive their primary care from BMC 
affiliated Family Medicine practices. Participants will be recruited based on these criteria: 
(1) aged 18-44 years; (2) HbA1c 6.1-6.3%; (3) alcohol consumption of less than four 
drinks per week; and (4) deemed eligible to exercise by their primary care provider. 
Criteria for exclusion to participate will be: (1) documented limitations that prevent 
participation in physical activity; (2) diagnosis of any chronic disease, including 
myocardial infarction (MI), stroke, and cancer; (3) consumption of greater than four 
drinks per week; (5) substance abuse; and (7) transient living situation.  
Mean change in HbA1C from baseline to post-intervention is expected to be 0.37% 
+/- 0.57 based on work by Miyauchi et al that compared the impact of accelerometers and 
pedometers on change in HbA1C levels in individuals with T2DM72. Based on an alpha of 
5%, beta of 80%, baseline mean HbA1C of 6.2%, and standard deviation of 1.1,  the 
estimated sample size to be recruited would be 14078. To account for the possibility of 
attrition from the study and to reduce the risk of bias, more participants will be recruited 
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for participation. Based on a dropout rate of 29% in the Miyauchi et al study, the 
recruitment sample size goal is 182, or 91 per group72. 
Intervention 
Participants will be matched by age, gender, race and ethnicity, and then 
randomized to one of two groups. All resources, materials, and interviews with study 
investigators will accommodate participant’s native language. The intervention will take 
place over one-year to account for seasonal variations in exercise levels and eating habits. 
Both the control and experimental groups will receive counseling for weight loss 
and healthy eating during the year of the intervention through participation in the CDC 
recommended Lifestyle Change Program through an affiliated local organization79. The 
Lifestyle Change Program combines targeted individual and group counseling sessions 
that focus on goal setting, healthy eating, increasing physical activity, and weight loss79. 
Participation in a Lifestyle Change Program has been shown to reduce the risk of T2DM 
in at risk individuals (see Preventing T2DM with lifestyle changes, Existing Research, 
page 18)8,10. Participants will meet weekly for the first six months of the CDC program, 
and once a month throughout the second six-month period.  
The experimental group will wear the Fitbit Flex2 wearable wrist device. The 
Fitbit Flex2 is the newest iteration of the Fitbit Flex. Participants will be educated on how 
to download and navigate the Fitbit App, set physical activity goals on the Fitbit App, 
and how to interact with peers using the App. Participants will be encouraged to review 
the owner’s manual for instruction on all other features. Additionally, participants in the 
experimental group will receive the LG Tribute HD smartphone with internet, data, and 
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Bluetooth access that allows participants to access the Fitbit App. Participants will be 
asked to wear the Fitbit Flex2 for greater than 10 hours a day, and synchronize the Fitbit 
Flex2 wrist device with the App on their smartphone daily. While the Fitbit Flex2 
measures many different data points such as calories burned, time spent asleep and 
awake, and step count, participants will be instructed to focus solely on minutes of 
physical activity and number of steps completed per day. 
Participants randomized to the standard intervention group will not wear a Fitbit 
Flex2 wrist device during the study.  
Both groups will have a daily physical activity goal of 150 mins of moderate-
intensity aerobic activity (“brisk walking”) per week as recommended by the CDC80.  
Participants in each group will be asked to track their physical activity each day in an 
electronic tracker that allows participants to document the amount of activity performed 
(type, number of minutes, and steps for the experimental group; type and number of 
minutes for the control group), type of activity, and their diet. This tracker will serve as 
an electronic diary to self-monitor progress towards goals. The tracker will also be used 
during check-ins for the CDC recommended Lifestyle Change Program, and quarterly 
check-ins with program registered nurse (RN) to provide feedback on progress and 
adherence to interventions. This electronic tracker and the data will be available to 
investigators as well. In addition to the above tracker, the enhanced intervention group 
will also have access to the Fitbit Flex2 mobile device App that allows one to self-
monitor physical activity and interact socially with other Fitbit App users. 
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Both groups will meet with an RN prior to the study start (baseline), and then 
every three months (five total). At these RN visits, participants will have their HbA1C and 
weight measured. The RN will also review the participant’s EPIC medical record for any 
new diagnoses, which include MI, stroke, and cancer, that would be cause for 
discontinuation of the study; and the electronic diary to confirm adherence to study 
protocol. Figure 4 outlines the RN and CDC program visit timeline throughout the study 
(APPENDIX A: TABLES AND FIGURES, page 53). 
Participants will be compensated with a $25 grocery store gift card per RN visit 
for their time and effort traveling to these visits.  
Study variables and measures 
The primary variable of interest in this study will be HbA1C. HbA1C will be 
measured pre-intervention and every three months (five measures total). The HbA1C will 
be measured via blood draw by the RN by a method certified by the NGSP29. 
Secondary variables of interest in this study include physical activity and BMI. 
Physical activity will be measured by the average weekly minutes of physical activity 
(reported for the experimental group, estimated for the control group), and average daily 
step count (weekly step count divided by seven) for the experimental group. BMI will be 
calculated by kilograms/meters2 at pre-intervention and every 3 months (5 measures 
total). See Table 4 for a list of primary and secondary variables to be measured 
(APPENDIX A: TABLES AND FIGURES, page 54). 
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Recruitment  
Investigators will have access to the electronic medical software Epic that is used 
at BMC. Investigators will review charts of all BMC Family Medicine patients and 
identify patients that meet the study inclusion criteria. Patients that meet the inclusion 
criteria will be notified via phone and mail correspondence and offered to participate in 
the study. Written informed consent will be required for all participants. 
Data collection 
Data will be collected every three months during participant visits to the study’s 
clinical office. During the visit, an RN hired by the study will draw blood, measure 
individuals weight, review participant’s electronic diary, and review participants’ EPIC 
chart. Chart review will consist of the RN conducting both a participant interview and 
review of the electronic medical record to identify if there are any new medical diagnoses 
or significant health events since the last study visit. New medical diagnoses or health 
events that would warrant discontinuation from the study include: MI, stroke, cancer, 
alcohol consumption greater than four drinks per week, documented physical limitations 
that prevent physical activity, glycemic medication administration, and substance abuse. 
HbA1C measurements conducted throughout the study that are elevated to levels that meet 
the criteria for diagnosis of T2DM will not be causal for removal of the study; instead, 
the participant’s Family Medicine provider will be notified as outlined in the data sharing 
agreement in the informed consent (see Institutional Review Board, page 40). 
Data will be transcribed into an Excel spreadsheet by research staff once 
laboratory results are received. Research staff will have access to electronic trackers and 
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will transfer physical activity (daily step count, type of activity, and minutes of physical 
activity for the experimental group; type and estimated minutes of physical activity for 
the control group). 
Data analysis 
A statistician will be consulted for assistance with the data analysis portion of this 
study. Descriptive statistics will be used to describe study group demographics by age, 
gender, and race/ethnicity. The primary outcome of interest is HbA1C which will be 
measured five times over the course of one year in both groups (baseline, three-months, 
six-months, nine-months 12-months). Changes in the HbA1C will be plotted over time. 
The mean change in HbA1C for the all participants in the experimental group will be 
calculated and compared to the mean change in HbA1C for all participants in the control 
group. Paired T-tests will be utilized to examine the statistical significance of the mean 
changes in HbA1C between the two groups. Statistical significance will be measured as p 
< 0.05. 
Descriptive statistics will be used to describe the study group secondary outcomes 
of interest, which include physical activity and BMI.  Physical activity will be reported as 
mean number of daily steps (experimental group), and mean number of minutes of 
exercise per week (both groups, per quarter). 
For data to be included in the analysis and not be washed out, participants must 
have entered > 70% of requested variables into the electronic tracker, and participants 
must have attended > 75% of scheduled check-ins, which include quarterly RN visits and 
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the CDC program meetings. In addition, the enhanced intervention group need to wear 
the Fitbit Flex2 device for > 10 hours for five or more consecutive days each week. 
Participants that also have newly documented health problems discovered during 
RN chart review, which include MI, stroke, cancer, initiation of any glycemic control 
medication, or change in physical activity capabilities, will be removed from the study 
and their data will not be included in analysis. 
Timeline  
Table 5. Study Timeline 
Pre-intervention: Six -
months to one-year 
• Submit IRB for approval 
• Obtain project funding and resources 
• Hire study staff 
• Participant recruitment  
• Distribute materials and education  
Intervention: One year • Data collection and entry 
• Participant compensation 
• CDC Lifestyle Change Program  
Post-intervention: 
One-year to 18 
months 
• Collect materials 
• Data analysis 
• Manuscript submission for peer-review 
 
Resources 
This study will require significant resources. Study staff will include a principal 
investigator ($50,000 per year), a co-investigator ($40,000 per year), a part time RN 
($30,000 one year), and a statistician ($20,000 one-time fee). The principal and co-
investigator will be responsible for all study oversight. A part-time RN will be 
responsible for blood draws and chart review. Data entry and collection will be 
completed by the principal investigator, the co-investigator, and RN. Total estimated cost 
of study staff over the proposed three-year study timeline is $320,000. 
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Use of a medical office space will be required that includes a private room for 
participant blood draws. Each participant will have a total of five blood draws throughout 
the one-year study, for a total of 910 blood draws. Collected blood will be sent to a local 
laboratory for HbA1C processing. Phlebotomy supplies will be needed for the blood 
draws, which include: gloves, alcohol wipes, gauze, band aids, tourniquets, 21-gauge 
butterfly needles, blood collection tubes, collection tube labels, and laboratory transport 
bags. A scale with the ability to measure both weight and height will also need to be 
purchased. 
Each participant will be enrolled in the CDC Lifestyle Change Program 
administered by an affiliated local organization. The cost of participation and enrollment 
will be covered by the study. For the experimental group, a total of 91 Fitbit Flex2 wrist 
devices, 91 smartphones, and 91 smartphone data and internet plans will need to be 
purchased.   
Grocery store gift cards for $25 will need to be purchased for participant 
compensation (910 total gift cards). Participant parking costs for quarterly RN visits will 
be reimbursed (910 total visits). 
Table 6 (page 41) outlines the required participant materials and their quantity. 
The total estimated cost of participant materials and supplies is $400,000. The total 
estimated cost of the study based on projected staff ($320,000) and participant material 
($400,000) costs is $720,000.  
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Table 6. Participant Materials 
Item Quantity 
CDC Program 182 
HbA1C Testing 910 (182 x 5 draws/participant) 
Fitbit Flex2 91 
LG Tribute HD Smartphone 91 
Smartphone Data Plan 91 
Grocery Store Gift Cards 910 (182 x 5 visits/participant) 
Parking Reimbursement 910 (182 x 5 visits/participant) 
 
Institutional Review Board 
The study design will be submitted electronically to the Boston University 
Medical Center IRB for full-board approval prior to initiation of the study81. Full-IRB 
approval is required because this study will collect personal and sensitive data via a 
device and an invasive blood draw procedure. The IRB proposal will consist of all 
requirements listed for online submission of the INSPIR II application81. All study 
personnel will complete the required Office of Human Affairs research training as it 
pertains to their role. 
Additionally, a data sharing clause with the Family Medicine provider will be 
included in the informed consent. Participants’ Family Medicine providers will be 
notified when HbA1C values are elevated above 6.5% for consideration of discontinuation 
in the study to safeguard the patient.  
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CONCLUSION 
Discussion 
This study has several strengths. First, the study design controls for confounding 
by restriction of eligible participants by the inclusion criteria, matching, and 
randomization. Second, the study results will be highly generalizable based on the diverse 
patient population of BMC and the inclusiveness of the study design. Historically, two 
giant short falls of the use of electronic wearable devices to promote health behavior 
change are that consumers need to be motivated to want a device to help them, and they 
need to be able to afford one19. For example, the IDEA Randomized Trial required 
participants to have access to a cellular phone, computer, and internet, thus limiting 
individual participation to those that are affluent and of a certain socioeconomic status17. 
As Patel et al observe, “perhaps for these reasons [motivation to use and 
affordability of devices], wearable devices seem to appeal to groups that might need them 
least,” namely young, healthy, and affluent individuals19. This study’s inclusion criteria 
will ensure that the effect of an electronic wearable device on HbA1C can be measured in 
individuals with prediabetes who may not be motivated for behavior change and from all 
socioeconomic classes.  
Lastly, this study will examine the extent to which electronic wearable devices 
facilitate behavior change in the form of physical activity and subsequently HbA1C. Patel 
et al state, “the successful use and potential health benefits related to these [electronic 
wearable] devices depend more on the design of the engagement strategies than on the 
features of their technology. Ultimately, it is the engagement strategies—the 
	43 
combinations of individual encouragement, social competition and collaboration, and 
effective feedback loops—that connect with human behavior”19. By controlling for 
engagement strategies between both groups, namely the CDC curriculum with lifestyle 
coaching and the electronic diary, this study will be able to deduce the impact of the 
Fitbit Flex2’s engagement strategies on physical activity and HbA1C. 
There are also several limitations to this study. First, participants will not be 
blinded to researchers, opening the door to potential bias during weekly CDC curriculum 
and quarterly RN check-ins. Second, this study timeline is short and may not capture a 
significant change in HbA1C in the enhanced intervention group. On the other hand, if a 
significant change in HbA1C is observed, would these changes be sustained long-term 
with continued use of the electronic wearable device and adherence to lifestyle goals and 
teaching from the CDC curriculum? The question of long-term use and impact of 
electronic wearable devices on health measures is important, especially as it has been 
observed that the majority of individuals stop using electronic wearable devices after a 
short time59. Thus, future studies examining the long-term impact of electronic wearable 
devices in prediabetics may be warranted. 
Lastly, there are numerous obstacles that may prevent sustained participation and 
result in participant burn out throughout the study. These obstacles include weekly and 
quarterly travel, regular use of the wearable device, daily documentation, and invasive 
blood draws. Yet, the study design attempts to prevent against potential participant burn 
out by compensating participants for their participation, and reimbursing for travel 
expenses to scheduled RN visits.  
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Summary 
There has been an increase in prevalence in Type 2 DM in both adults and those 
less than 20 years of age due primarily to the rise in obesity and physical inactivity 
among Americans2,14,15.  
Literature has demonstrated the utility of wearable devices that track daily step 
counts in motivating individuals to increase the amount of physical activity performed 
with promising results in the form of behavior changes and outcome measures such as 
decreased HbA1C in individuals with T2DM, increase in physical activity, and weight 
loss16–18,21,72. These findings coincide with reports of the increasing consumer popularity 
of electronic wearable devices, with almost 25% of Americans owning an electronic 
wearable device13,71. Additionally, these findings highlight the promise of electronic 
wearable devices as medical interventions. Disease and the risk for disease development 
could serve as the motivating force for the use of electronic wearable devices to track 
physical activity in certain individuals, particularly those at risk of developing T2DM. 
Current literature focuses on the impact of electronic wearable devices on HbA1C 
in individuals already diagnosed with T2DM. Yet, the impact that these devices have on 
individuals with prediabetes is not widely researched. This study aims to fill that gap by 
studying the role the Fitbit Flex2 wrist device has on HbA1C in prediabetics in the short-
term.   
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Clinical and public health significance 
The economic burden DM places on society and those with the disease is 
enormous. The ADA estimated in 2012 that the total cost of diagnosed DM was $245 
billion, an almost 41% increase from the 2007 estimate82. Of that total, $176 billion was 
attributed to medical costs which consisted of hospitalization, medications, supplies, and 
office visits. Decreased productivity in the work force accounted for the remaining $69 
billion, which included absenteeism from work, decreased productivity, and lost 
productivity due to early mortality. At the individual level, they reported that those with 
DM have 2.3 times higher medical expenditures than those without DM82.  
Access to DM care disproportionately affects the uninsured and minorities. The 
ADA found that those without health insurance had 79% fewer office visits and were 
prescribed 68% fewer DM medications than those with insurance82. Additionally, per-
capita healthcare expenditures were lowest among Hispanics when compared to blacks 
and non-Hispanic whites82. A 2014 analysis by Chen et al found that while the 
Affordable Care Act has decreased the uninsured rates in all groups, Latinos[Hispanics] 
remained the group with the highest uninsured rate83.  Considering the high incidence rate 
of DM, decreased access to care, and decreased health care spending among Hispanics, it 
may be concluded that Hispanics are at risk of many of the long-term complications of 
DM.  
While the ADA analysis considers the economic costs associated with diagnosed 
DM, it does not consider those with undiagnosed DM or those that have prediabetes. Two 
analyses conducted by Zang et al estimated that the additional healthcare cost associated 
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with the 6.3 million U.S. adults with undiagnosed DM and 57 million adults with 
prediabetes was $18 billion and $25 billion, respectively84,85.  
Additionally, as DM is a major risk factor for the development of CVD, the 
increasing prevalence of T2DM raises concern for the increase in future CVD related 
events such as MI and stroke2,6. Studies have described the risk of future cardiac events in 
individuals with T2DM with no history of coronary artery disease approaches the risk of 
future cardiac events in patients with established coronary artery disease and prior MI86–
88. Such an elevated risk for future cardiac events in individuals with T2DM, while also 
acknowledging the economic burden of DM, emphasizes the need for identification and 
timely intervention of risk factors of T2DM92.  
Commonly used interventions employed by medical providers to curtail the 
incidence in T2DM include physical activity, diet, and medications25. Yet, as Bonato 
observes, “physicians [often] have to infer the effectiveness” of these interventions “from 
observations performed in the clinical setting and from patients’ feedback”60. The 
findings from this proposed study may support the potential of wearable electronic 
devices to bridge that gap, enabling medical professionals the ability to monitor progress 
towards physical activity goals and use data to tailor interventions for prediabetes and 
T2DM prevention; additionally, these devices may allow patients the opportunity to self-
monitor their own progress towards goals. Due to their ubiquity and ability to engage, 
motivate, and enhance already proven disease modifying interventions, electronic 
wearable devices show promise in becoming a mainstay in preventive and prescribed 
therapies for T2DM.     
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APPENDIX A: FIGURES AND TABLES 
 
Figure 1. Rates of Diagnosed Diabetes by Race and Ethnicity, 2012 
Source: Taken from Statistics About Diabetes. American Diabetes Association. http://www.diabetes.org/diabetes-
basics/statistics/. Accessed July 15, 2017. 
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Table 1. Characteristics and Classification of DM 
 
Abbreviations: DM, Diabetes Mellitus; FPG, fasting plasma glucose; HbA1C, hemoglobin A1C; 2-h PG, 2-hour plasma 
glucose. 
Source: Adapted from Statistics About Diabetes. American Diabetes Association. http://www.diabetes.org/diabetes-
basics/statistics/. Accessed July 15, 2017. 
Note: An initial positive screening test should be confirmed by a second test shortly after the initial positive screen test, 
unless a clinical diagnosis is clear due to symptoms29. The ADA recommends using the same test used to screen to 
confirm a diagnosis of T2DM, as the ADA states that the same test will have a “greater likelihood of concurrence”29. 
Often a FPG and HbA1C are performed together as elevations in both confirm T2DM diagnosis29. Conversely, if two 
tests are performed and one is elevated and the other is normal, the result of the test that is elevated should be repeated 
to confirm a diagnosis of T2DM29. 
Type of 
Diabetes Pathogenesis 
FPG 
(mg/dL) 
2-h PG 
(mg/dL) 
HbA1C 
(%) 
Typical Age of 
Onset 
Prediabetes Abnormal glucose 
homeostasis 
100-125 140-199 5.7-6.4 Precedes both Type 1 and Type 2 
DM 
Type 1 
Beta cell 
destruction 
and insulin 
deficiency 
³ 126 ³ 200 ³ 6.5 
Typically, before 
20-30 years of age 
Type 2 Insulin resistance or 
deficiency 
Adult; risk 
increases with 
advanced age 
Gestational 
Insulin 
resistance due 
to metabolic 
changes in 
pregnancy 
Develop during 
pregnancy; 
majority revert 
back to normal 
glucose tolerance 
postpartum; 
increased risk of 
developing DM 
Other 
Defects 
pertaining to 
insulin: 
genetic, 
metabolic, 
mitochondrial, 
host factors 
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Table 2. Risk Factors for Prediabetes and T2DM 
Age > 45 years  
Family history of DM  
Physical Inactivity 
Obesity – Body Mass Index (BMI) ³ 25 kg/m2, abdominal obesity 
Race and ethnicity - African American, Hispanic, Asian, Pacific Islander, or Native-
American ethnicity  
History of gestational diabetes or delivery of infant weighing ≥9 lb  
Previously identified with prediabetes 
Polycystic ovary syndrome  
Cardiovascular disease 
Hypertension 
Dyslipidemia 
 
Abbreviations: DM, Diabetes Mellitus; BMI, body mass index. 
Source: Adapted from Statistics About Diabetes. American Diabetes Association. http://www.diabetes.org/diabetes-
basics/statistics/. Accessed July 15, 2017; and Vijan S. Type 2 Diabetes. Ann Intern Med. 2015;162(5):ITC1. 
doi:10.7326/AITC201503030. 
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Table 3. Prediabetes and T2DM Screening Recommendations 
ADA USPSTF CDC 
Frequency: Screening 
every three years 
 
Adults with elevated BMI 
and one or more additional 
risk factor 
 
Beginning at 45 years old 
in individuals with no risk 
factors 
 
Test: HbA1c, FPG, 2-h PG 
Frequency: Screening every 
three years 
 
Part of CVD assessment in 
obese adults between ages 
of 40-70 years old 
 
Test: HbA1c, FPG, 2-h PG 
Adults > 45 years old or 
those with risk factors 
 
Test: HbA1c, FPG, 2-h PG 
 
Abbreviations: ADA, American Diabetes Association; BMI, body mass index; CVD, cardiovascular disease; FPG, 
fasting plasma glucose; HbA1C, hemoglobin A1C; T2DM, type 2 Diabetes Mellitus; 2-h PG, 2-h plasma glucose. 
Source: Adapted from Screening for type 2 diabetes mellitus - UpToDate. https://www.uptodate.com/contents/ 
screening-for-type-2-diabetes-mellitus. Accessed August 7, 2017; and Siu AL, U S Preventive Services Task Force. 
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force 
Recommendation Statement. Ann Intern Med. 2015;163(11):861-868. doi:10.7326/M15-2345. 
Note: An initial positive screening test should be confirmed by a second test shortly after the initial positive screen test, 
unless a clinical diagnosis is clear due to symptoms29. The ADA recommends using the same test used to screen to 
confirm a diagnosis of T2DM, as the ADA states that the same test will have a “greater likelihood of concurrence”29. 
Often a FPG and HbA1C are performed together as elevations in both confirm T2DM diagnosis29. Conversely, if two 
tests are performed and one is elevated and the other is normal, the result of the test that is elevated should be repeated 
to confirm a diagnosis of T2DM29. 
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Figure 2: Fitbit App Desktop Dashboard 
Source: Taken from Fitbit App & Dashboard. https://www.fitbit.com/app. Accessed August 10, 2017. 
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Figure 3: Fitbit App Mobile Dashboard 
Source: Take from Fitbit App & Dashboard. https://www.fitbit.com/app. Accessed August 10, 2017. 
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Abbreviations: C, CDC Lifestyle Change Program Visit; CDC, The Centers for Disease Control and Prevention; RN, 
registered nurse visit. 
Figure 4. Visit Timeline 
Note: RN1-RN5: these visits occur every three months and are conducted by the study RN; each participant will have 
their blood drawn for a HbA1C measure, their weight taken, and the RN will conduct a health interview and review the 
patient’s electronic medical record and diary. C1-C24: these are weekly visits as a participant in the CDC Lifestyle 
Change Program; participants from both study arms will be enrolled in this program; participants will participate in 
individual and group counseling sessions and use their electronic diary to review goal progress with program staff 
during these visits. C25-C30: these are monthly visits as a participant in the CDC Lifestyle Change Program. 
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Table 4. List of Primary and Secondary Variables 
 
Abbreviations: BMI, body mass index; HbA1C, hemoglobin A1C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Recorded Daily Calculated Weekly 
Measured 
Every Three 
Months 
Experimental 
Group - Fitbit 
Flex2 
Steps 
 
Activity type 
 
Minutes of activity 
Average daily step 
count 
 
Average minutes of 
activity 
HbA1C  
 
Weight/BMI 
Control Group 
Activity type 
 
Minutes of activity 
Average minutes of 
activity (estimated) 
HbA1C  
 
Weight/BMI 
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APPENDIX B: DEVICE ACCURACY 
A systematic review completed by Evenson et al looked at studies that explored 
the validity and reliability of devices produced by Fitbit and Jawbone and found that 
these devices were highly accurate at estimating step count when compared to direct 
observation and an objective assessment from a research grade accelerometer89. They 
chose to focus on Fitbit and Jawbone because they were the most represented devices in 
the marketplace at the time89. The studies that they examined looked at devices mostly 
worn at the hip/waist and wrist. A summary of their findings suggest that hip-based 
devices tended to be more accurate with step count than devices worn at the wrist.  and 
When errors were present and high, they were likely an under-estimation of step count 
most likely during periods of slow walking for wrist-worn devices89. Work by Diaz et al 
that is included in the systematic review examines the validity of two Fitbit devices, the 
Fitbit One that is worn on the hip and the Fitbit Flex that is worn on the wrist, reflect 
these findings65. They compared the estimated Fitbit step counts to the observed step 
counts and found that the “correlation of Fitbit-estimated step counts to observed step 
counts (Fitbit count/observed count) was 0.97–0.99 for all hip devices and 0.77–0.85 for 
wrist devices”65. The mean difference in step counts were higher in the wrist worn 
device, ranging from − 3.1 (standard deviation (SD) 8.9) to − 0.3 (SD 2.0) steps and 
− 26.3 (SD 25.2) to − 2.9 (SD 8.4) steps for the hip- and wrist-based devices”65. 
Additionally, they found that “the greatest differences were seen in the wrist-based Fitbit 
during slow, moderate, and brisk walking as step counts were underestimated during 
these stages by 16.3%, 10.6%, and 11.3%, respectively”65.  
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In regards to device placement, Diaz et al note in a subsequent study that “the hip 
has been the conventional attachment site for accelerometers because of its proximity to 
the human body’s center of mass (hence providing a more accurate measure of 
activity)”64. Yet they report that there have been issues in compliance with hip-based 
accelerometers in previous studies because of discomfort and inconvenience64. The 
growing popularity of wrist-based electronic wearable devices presents an alternative to 
measure physical activity and improve compliance during research trials. Though slight 
differences exist in step count between wrist-based devices and hip-based devices, these 
differences can be minimized by instructing individuals to focus on moving their arms 
when performing movement activities20,64,65,89,90. 
The above systematic review and study examined the accuracy of devices in 
controlled laboratory settings. Dominick et al set out to examine the accuracy of step 
count for the Fitbit Flex wrist device on participants in free-living conditions66.  They 
compared the Fitbit Flex to the research grade ActiGraph GT3X worn at the hip in 19 
healthy men and women between the ages of 19 and 37 years of age with a range of 
BMIs. The ActiGraph GT3X triaxial accelerometer was used because, as Napolitano et al 
state, it has been shown to be the most reliable and generalizable with physical activity 
measures when compared to other available accelerometers91.  Dominick et al relied on 
participants to document the type of activity performed each day into one of six 
categories that were later consolidated to run/sports, cardio machine, or walking. They 
also defined the intensity of physical activity based on step count cut off points. Step 
count data was collected over two-seven day periods and reported as the mean 
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steps/minute and the average daily steps66. The analyzed data showed that there was no 
significant difference between the daily step count between the Fitbit Flex and the 
ActiGraph GT3X (r = 0.91, p = 0.10)66. However, the authors found there was a higher 
correlation in steps/minute between devices during walking (r = 0.80, p = 0.346) and 
run/sports (r = 0.73, p = 0.377) than in the cardio machine (r = 0.52, p = 0.619) 
exercise66. The authors cite literature that suggest these differences may be explained by 
device placement, as well as error estimates may be influenced by activities with varying 
intensity levels when examined combined versus examined separately 92,93.  
Huang et al set out to explore the accuracy of eight different electronic wearable 
devices during level walking at various speeds and stair walking63. The devices were 
worn at either the wrist (Nike+ Fuelband, Garmin Vivofit, Fitbit Flex, and Jawbone UP) 
or hip (Yamax CW-701, Omron HJ-321, Fitbit One, and Fitbit Zip) in 40 healthy 
individuals in their mid-20’s. The authors reported that the hip-based devices were more 
accurate than wrist-based devices, with the Nike+ Fuelband being the least accurate 
device for measuring steps. Stair walking was generally underestimated by step count by 
all devices. Additionally, there was no significant difference in walking speed and step 
count accuracy except for the Fitbit One and Nike+ Fuelband devices63. This study 
supports the earlier referenced studies that illustrated the differences in step count 
accuracy of wearable devices based on body position and type of device, while also 
identifying that step count as recorded by electronic wearable devices may not be 
accurate if activities involve stairs63. 
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While these data support the accuracy of Fitbit devices at measuring step count 
while acknowledging that performance relies on body placement in healthy individuals, 
they illicit questions regarding generalizability of findings to other populations such as 
those with chronic disease. Of the 22 studies included in the systematic review by 
Evenson et al, nearly all studies had inclusion criteria limiting participants to those that 
are healthy and without significant morbidity that would limit them or interfere with 
testing89. Another systematic review, by Van Remoortel et al, set out to examine the 
validity of physical activity measures such as steps collected by electronic wearable 
devices in healthy and chronic disease populations67. Their findings also suggest that 
electronic wearable device step counts are less accurate at slow walking speeds. As those 
with chronic diseases may develop gait changes and walk more slowly, the authors 
indirectly propose that electronic wearable devices may be less accurate in counting steps 
in individuals with chronic disease67,94,95. Similarly, those that are older have been shown 
to spend more time performing low intensity activities, such as slow walking, and may 
also have less accurate steps counts96,97. 
Van Remoortel et al point out that of the 40 studies included in their review, 88% 
were of healthy individuals and only 12% were studies where electronic wearable devices 
were used to collect physical activity measures in individuals with chronic diseases such 
as chronic obstructive pulmonary disease (COPD), chronic heart failure, obesity, and 
T2DM67. Additionally, inclusion criteria required all studies to be performed between 
January 2000 and March 2012, therefore examining the validity of devices that currently 
are between five and 17 years old. None of the included studies used the more market 
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popular devices from Fitbit. Therefore, it is difficult to generalize their findings to groups 
with chronic diseases that may use newer and more popular electronic wearable devices 
to track step count. The authors subsequently proposed that there needs to be specific 
validation studies performed in these groups67.  
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